New drug cocktail aims to shrink lung tumors before surgery
NCT ID NCT07586202
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether giving a combination of amivantamab and either lazertinib or chemotherapy before surgery can shrink or stop the growth of EGFR-mutated non-small cell lung cancer. About 68 people with stage II-IIIB lung cancer that can be surgically removed will participate. The main goal is to see how many patients have very few or no cancer cells left in the removed tumor tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
amivantamab and lazertinib or chemotherapy (carboplatin and pemetrexed)
What this could lead to
If successful, this could offer a new treatment option before surgery to shrink or eliminate EGFR-mutated lung cancer, potentially improving long-term outcomes.
What could go wrong
This is an early Phase 2 trial with only 68 participants, so results may not apply to everyone. Side effects from the drug combinations could be significant, and the treatment may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••